EPRX · Eupraxia Pharmaceuticals Inc.

Eupraxia’s Q1 2026 results reflect a deliberate strategic pivot toward EP-104GI, evidenced by a near-tripling of R&D expenses to $11.2M (from $3.8M year-over-year), largely attributable to scaling the RESOLVE Phase 1b/2a trial in eosinophilic esophagitis. The $12.7M net loss—though larger than last year’s $6.8M—was partially offset by $3.3M in other income, including $2.2M in foreign exchange gains and $1.1M in interest income, reflecting its U.S. dollar-denominated short-term investment portfolio. Crucially, the company executed a successful $63.2M gross public offering in February 2026, generating $58.6M in net proceeds, which—combined with existing cash and short-term investments—delivered $138.9M in total liquid assets as of March 31, 2026. Management explicitly stated this positions the company to fund operations into the second half of 2028, well beyond key upcoming catalysts including interim Phase 2b RESOLVE data expected in Q4 2026 and progression toward Phase 3 trials for EP-104GI. The shift away from EP-104IAR (osteoarthritis) is confirmed in both the MD&A and press release: capital previously earmarked for EP-104IAR development is now being redirected to advance EP-104GI, supported by strong 36-week clinical data showing near-complete histological improvement and sustained symptom relief. This reallocation underscores a de-risking strategy centered on a single lead candidate with compelling early data, rather than parallel development. While general and administrative expenses rose 46% year-over-year to $4.8M—consistent with Nasdaq listing compliance and public company infrastructure—the company remains unprofitable and has no revenue, reinforcing its status as a pure-play clinical-stage biotech reliant on continued capital raises. The absence of any material weaknesses in internal controls or disclosure deficiencies—certified jointly by the CEO and CFO—adds credibility to the financial reporting framework ahead of upcoming clinical milestones.